HC Wainwright Reaffirms Buy Rating for Precigen (NASDAQ:PGEN)

HC Wainwright restated their buy rating on shares of Precigen (NASDAQ:PGEN) in a research note issued to investors on Friday morning,Benzinga reports. The firm currently has a $4.00 price objective on the biotechnology company’s stock. HC Wainwright also issued estimates for Precigen’s FY2026 earnings at $0.01 EPS, FY2027 earnings at $0.22 EPS and FY2028 earnings at $0.39 EPS.

Several other research analysts have also recently weighed in on PGEN. StockNews.com upgraded shares of Precigen to a “sell” rating in a research report on Thursday, August 1st. JMP Securities decreased their price objective on shares of Precigen from $14.00 to $7.00 and set a “market outperform” rating on the stock in a research report on Thursday, August 15th. Two investment analysts have rated the stock with a sell rating and four have given a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $7.00.

Precigen Stock Performance

Shares of NASDAQ:PGEN traded down $0.06 on Friday, hitting $0.82. The company’s stock had a trading volume of 1,777,639 shares, compared to its average volume of 741,176. The company has a 50-day simple moving average of $0.92 and a 200 day simple moving average of $1.24. Precigen has a 1 year low of $0.78 and a 1 year high of $1.93.

Precigen (NASDAQ:PGEN) last posted its quarterly earnings data on Wednesday, August 14th. The biotechnology company reported ($0.10) earnings per share for the quarter, missing the consensus estimate of ($0.09) by ($0.01). The company had revenue of $0.72 million during the quarter, compared to the consensus estimate of $1.28 million. Precigen had a negative return on equity of 112.05% and a negative net margin of 3,521.68%. As a group, equities analysts predict that Precigen will post -0.44 EPS for the current fiscal year.

Institutional Trading of Precigen

Large investors have recently added to or reduced their stakes in the stock. ClariVest Asset Management LLC boosted its holdings in shares of Precigen by 2.9% during the 2nd quarter. ClariVest Asset Management LLC now owns 492,152 shares of the biotechnology company’s stock valued at $778,000 after buying an additional 13,752 shares in the last quarter. SG Americas Securities LLC boosted its stake in Precigen by 44.2% in the 3rd quarter. SG Americas Securities LLC now owns 45,063 shares of the biotechnology company’s stock worth $43,000 after purchasing an additional 13,823 shares in the last quarter. Exchange Traded Concepts LLC boosted its stake in Precigen by 10.2% in the 3rd quarter. Exchange Traded Concepts LLC now owns 167,496 shares of the biotechnology company’s stock worth $159,000 after purchasing an additional 15,525 shares in the last quarter. Stifel Financial Corp lifted its position in Precigen by 94.9% during the third quarter. Stifel Financial Corp now owns 32,200 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 15,680 shares during the period. Finally, The Manufacturers Life Insurance Company boosted its stake in shares of Precigen by 40.7% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 56,998 shares of the biotechnology company’s stock worth $90,000 after buying an additional 16,486 shares during the last quarter. Institutional investors own 33.51% of the company’s stock.

Precigen Company Profile

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.